PHAGE THERAPY REGULATORY FRAMEWORK AND LEGAL LIABILITY

INTRODUCTION

Phage therapy is an emerging medical treatment that uses bacteriophages, which are viruses that selectively infect bacteria, to treat bacterial infections. It is being investigated as an alternative or complementary approach to conventional antibiotics, particularly in cases involving antimicrobial resistance and difficult-to-treat bacterial infections.

Phage therapy raises important legal and regulatory questions concerning biological-product classification, manufacturing standards, clinical-trial approval, patient consent, biosafety, product quality, intellectual property, environmental safety and post-treatment monitoring.

In India, there is currently no separate comprehensive legislation exclusively governing phage therapy. Its regulation must therefore be considered under the Drugs and Cosmetics Act, 1940, the Drugs Rules, 1945, the New Drugs and Clinical Trials Rules, 2019, applicable biological-product requirements and relevant biomedical research and biosafety guidelines.

1. LEGAL AND REGULATORY FRAMEWORK IN INDIA

The principal legal instruments relevant to phage therapy include:

Drugs and Cosmetics Act, 1940: Provides the statutory framework for regulating drugs, including applicable biological therapeutic products.

Drugs Rules, 1945: Establish requirements concerning drug manufacturing, licensing, quality control, labelling and distribution.

New Drugs and Clinical Trials Rules, 2019: Govern clinical investigations, new-drug permissions, ethics committee approval and clinical-trial responsibilities.

Environment (Protection) Act, 1986: Provides environmental protection requirements relevant to regulated biological activities.

Biological Diversity Act, 2002: May apply where regulated biological resources are accessed for research or commercial purposes.

ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017: Establish ethical standards for human-participant research.

Consumer Protection Act, 2019: Provides remedies where applicable for defective products and deficient medical services.

The precise regulatory pathway depends on the product's intended use, composition, manufacturing status and whether it is being used in research or clinical treatment.

2. PHAGE THERAPY PRODUCT APPROVAL AND LICENSING

A bacteriophage preparation intended for therapeutic use must undergo the regulatory assessment applicable to its classification as a drug or biological product.

The manufacturer or sponsor must establish:

Appropriate regulatory classification.

Applicable manufacturing and product permissions.

Evidence supporting identity, quality, safety and therapeutic performance.

Qualified manufacturing and quality-control personnel.

Documented quality-management procedures.

Appropriate product labelling and storage arrangements.

Regulatory authorisation before unauthorised commercial distribution.

Experimental phage preparations must not automatically be treated as approved medicines. Their clinical use must comply with applicable legal permissions and ethical requirements.

3. MANUFACTURING AND QUALITY-CONTROL COMPLIANCE

Manufacturing compliance is essential because therapeutic phage products are biological preparations requiring strict quality assurance.

Important regulatory requirements include:

Qualification and traceability of biological starting materials.

Compliance with applicable Good Manufacturing Practices.

Quality assurance and independent quality-control oversight.

Appropriate product identity and purity assessment.

Verification of product consistency and stability.

Prevention of unintended contamination.

Validation of relevant manufacturing and testing processes.

Complete batch documentation.

Investigation of deviations and corrective actions.

Proper release procedures before distribution.

Manufacturers must maintain reliable records demonstrating that products meet their approved specifications.

4. BIOSAFETY AND BIOSECURITY REQUIREMENTS

Phage therapy research involves biological agents and therefore requires appropriate institutional biosafety governance.

Institutions must establish risk assessments, appropriate containment arrangements, trained personnel, documented safety procedures and incident-reporting systems.

Research involving genetically modified organisms or regulated recombinant biological material may attract additional requirements under applicable environmental and biosafety legislation.

Institutions must also ensure that biological materials are handled only by appropriately authorised personnel and that relevant waste is managed in accordance with applicable regulations.

5. CLINICAL TRIALS AND PATIENT CONSENT

Clinical investigations involving phage therapy must comply with applicable clinical-trial requirements.

The New Drugs and Clinical Trials Rules, 2019 establish the framework for regulatory permission, ethics committee review and protection of human research participants.

Important requirements include:

Prior regulatory authorisation where required.

Approval from an appropriately constituted Ethics Committee.

Voluntary and informed patient consent.

Scientifically justified research protocols.

Appropriate documentation of treatment outcomes.

Reporting of serious adverse events.

Compliance with applicable compensation requirements.

Protection of confidential patient information.

Patients must be informed about the experimental status of the treatment, possible benefits, uncertainties and foreseeable risks.

6. COMPASSIONATE USE AND EXPERIMENTAL PHAGE THERAPY

Compassionate use refers to access to an investigational treatment for patients suffering from serious conditions when satisfactory authorised alternatives may be unavailable.

Phage therapy may raise compassionate-access questions, particularly in difficult-to-treat bacterial infections.

However, compassionate use must not be confused with unrestricted clinical administration.

Important legal safeguards include:

Appropriate regulatory consultation and permissions.

Medical justification for experimental treatment.

Patient or authorised representative consent.

Independent ethical oversight where required.

Documentation of treatment decisions.

Monitoring and reporting of adverse events.

Appropriate responsibility of treating physicians and sponsoring institutions.

The Declaration of Helsinki provides internationally recognised ethical principles for medical research involving human participants. It does not independently replace Indian statutory approval requirements.

7. INTELLECTUAL PROPERTY AND COMMERCIALISATION

Phage therapy creates intellectual-property questions involving naturally occurring bacteriophages, engineered biological products, therapeutic formulations and manufacturing technologies.

The Patents Act, 1970 is relevant to patent protection.

Section 3(c) excludes the discovery of a living thing or non-living substance occurring in nature from patentability.

Section 3(j) excludes plants and animals, in whole or in part, other than microorganisms, but its application must be considered alongside other statutory exclusions and patentability requirements.

Commercial developers must also respect confidentiality, licensing agreements, research ownership and applicable biological-resource access requirements.

8. JUDICIAL PRECEDENTS AND RELEVANT CASE LAWS

There is currently no established reported Indian Supreme Court judgment specifically determining the regulatory legality of bacteriophage therapy. The following cases provide direct or analogous principles relevant to its governance.

1. Yash Charitable Trust v. Union of India (2026 INSC 96) — Analogous Authority

The Supreme Court considered the regulation of unproven stem-cell treatments and held that experimental interventions cannot be promoted as routine clinical services outside the applicable approved research and clinical-trial framework.

The judgment is relevant by analogy to unproven phage treatments, particularly regulatory approval, clinical evidence, informed consent and protection against misleading therapeutic claims. It does not directly decide phage therapy regulation.

2. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1 — Analogous Authority

The Supreme Court explained the requirements of valid informed consent in medical treatment. Its principles apply to experimental phage therapy where patients must understand the treatment's experimental nature, uncertainties and foreseeable risks.

3. Jacob Mathew v. State of Punjab (2005) 6 SCC 1 — Analogous Authority

The Supreme Court explained the legal standards governing medical negligence and professional responsibility. This judgment is relevant where physicians or institutions negligently administer experimental biological treatments.

4. Indian Medical Association v. V.P. Shantha (1995) 6 SCC 651 — Analogous Authority

The Supreme Court examined the applicability of consumer-protection legislation to medical services. Its principles may support claims involving deficient medical services, defective therapeutic preparations or misleading treatment representations.

5. Parmanand Katara v. Union of India (1989) 4 SCC 286 — Analogous Authority

The Supreme Court emphasised the importance of preserving human life and providing timely medical assistance. Its principles are relevant to the treatment of patients with serious infections and the responsibility of medical institutions to provide appropriate emergency care.

6. Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996) 4 SCC 37 — Analogous Authority

The Supreme Court recognised the State's constitutional responsibility to provide adequate medical facilities under Article 21. This principle supports public-health initiatives addressing antimicrobial resistance and access to appropriate treatments.

7. Vellore Citizens' Welfare Forum v. Union of India (1996) 5 SCC 647 — Analogous Authority

The Supreme Court recognised the precautionary principle and polluter-pays principle in environmental protection. These principles are relevant to responsible disposal of biological research waste and environmental safeguards in pharmaceutical manufacturing.

9. PENALTIES AND LEGAL LIABILITY

Non-compliance may result in regulatory action, manufacturing restrictions, suspension of permissions, product seizure, clinical-trial termination and prosecution where statutory offences are established.

Potential liability includes:

Manufacturing or distributing drugs without required licences.

Marketing unapproved therapeutic products.

Conducting unauthorised clinical trials.

Concealing serious adverse events.

Negligent medical administration.

Misleading advertising and unsupported therapeutic claims.

Violations of applicable biosafety and environmental requirements.

The Drugs and Cosmetics Act, 1940 provides penalties for relevant statutory violations, while civil and consumer remedies may also be available.

10. PRACTICAL COMPLIANCE REQUIREMENTS

Phage therapy research institutions, manufacturers and healthcare providers should establish:

Regulatory classification and approval documentation.

Appropriate manufacturing and quality-control systems.

Institutional biosafety and ethical oversight.

Clinical-trial permissions where required.

Proper informed-consent procedures.

Traceability of biological products.

Patient safety and adverse-event monitoring.

Accurate labelling and therapeutic claims.

Secure storage and distribution arrangements.

Environmental and biomedical waste compliance.

CONCLUSION

Phage therapy represents an important emerging area of biotechnology and antimicrobial treatment. However, its clinical development requires appropriate pharmaceutical regulation, manufacturing quality assurance, biosafety oversight, clinical-trial authorisation and patient protection.

In India, the Drugs and Cosmetics Act, 1940 and the New Drugs and Clinical Trials Rules, 2019 provide relevant regulatory foundations, although a dedicated phage therapy regulatory framework remains underdeveloped. Judicial principles concerning informed consent, medical negligence, constitutional healthcare obligations and environmental protection provide additional safeguards. Establishing clear national regulatory standards would improve scientific accountability, patient safety and responsible development of bacteriophage-based medicines.